Series C funding sends Biofourmis to near-unicorn status
Add BT as a preferred source
Singapore
HOMEGROWN startup Biofourmis has raised US$100 million in a Series C equity round led by Softbank Vision Fund 2, catapulting the healthcare company to near-unicorn status in a matter of months.
The latest funding, which sources said has quadrupled Biofourmis' valuation from about US$200 million previously, comes despite a slowdown in healthcare investments in the Asia-Pacific over the first half of the year.
TRENDING NOW
Abandoned ‘Titanic’, failing ‘ancient towns’: Why China’s tourism boom leaves white elephants behind
Private equity giant Carlyle can grow bigger but needs to stay on its toes: co-founder David Rubenstein
Singapore to establish over-the-counter gold clearing system, central bank vaulting by end-2026
Singapore public sector commands highest AI salary premium as job postings surge: PwC study
